House Bill 624 would create a new “Prescription Drug Transparency” article in Chapter 90 of the North Carolina General Statutes. The bill is aimed at increasing visibility into prescription drug pricing by requiring manufacturers to notify interested parties before substantial price increases and when new drugs are introduced, and to provide supporting disclosures such as justifications for the price, marketing budgets, acquisition costs when applicable, and prior price histories. It also requires manufacturers or their agents to disclose to prescribers when a marketed drug contains an ingredient known to pose a risk of dependency.
The bill directs the Secretary of Health and Human Services to assess civil penalties of up to $1,000 per day for failures to report required information, with proceeds going to the Civil Penalty and Forfeiture Fund. It also requires DHHS to develop an implementation plan, create a public online portal for the required notifications and disclosures, and submit annual reports identifying the most frequently prescribed drugs, the costliest drugs, and drugs with the largest year-over-year cost increases. The act would take effect October 1, 2025, and it explicitly states that it does not limit a manufacturer’s ability to charge any price otherwise permitted by law.
HB624 would add a new state transparency framework affecting prescription drug manufacturers, prescribers, DHHS, insurers, health care service plan providers, pharmacy benefits managers, and state agencies that purchase or prescribe drugs. It would not impose direct price controls, but it would create new reporting, disclosure, and public-data obligations and authorize civil penalties for noncompliance. The bill would also require DHHS to build administrative systems for data collection, public access, and annual reporting, thereby expanding state oversight of drug pricing practices and market trends.
Based on the bill text and the absence of recorded committee testimony or votes, the measure appears to be framed as a consumer- and accountability-focused transparency bill rather than a regulatory price cap. Its sponsors suggest support for greater disclosure around drug pricing and marketing, and the inclusion of a no-price-limitation clause indicates an effort to address concerns about overregulation. Because there is no recorded debate or vote history in the provided materials, there is no documented opposition or support beyond the bill’s stated policy goals.
The main likely point of contention is the burden the bill places on drug manufacturers, who would have to provide advance notice and detailed disclosures about price increases and new products, as well as comply with public reporting requirements and potential penalties. Manufacturers may also object to the disclosure of marketing budgets, acquisition prices, and prior price schedules, which could be viewed as commercially sensitive. On the other side, supporters would likely emphasize the need for transparency, accountability, and prescriber awareness of dependency risks, especially given rising drug costs and public concern over pharmaceutical pricing.